Esperion Settles Patent Dispute, Delaying Generic Drugs Until 2040

Key Facts

1Esperion reached a settlement agreement with Renata Limited to protect patents for NEXLETOL and NEXLIZET.

2Renata agreed not to market generic versions of the drugs in the United States prior to April 19, 2040.

Esperion reached a settlement agreement with Renata Limited to protect patents for its cholesterol-lowering drugs NEXLETOL and NEXLIZET. Reuters reported that Renata agreed not to market generic versions of these drugs in the United States prior to April 19, 2040.

The agreement resolves patent litigation triggered by Renata’s Abbreviated New Drug Applications (ANDAs), securing long-term market exclusivity for Esperion. The company, which is wholly-owned by ARCHIMED, aims to maintain revenue stability and protect its therapeutic innovations through this settlement.